Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135427 · ClinicalTrials.gov registry record · Phase 4
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
A Phase 4 study of COPD and Alpha 1-Antitrypsin, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07135427 is a Phase 4 study of COPD and Alpha 1-Antitrypsin that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07135427, a Phase 4 study of COPD and Alpha 1-Antitrypsin, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
Conditions Studied
Interventions
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07135427
The ClinicalTrials.gov registry entry for NCT07135427 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with COPD appearing as the primary indexed condition, and to 1 intervention - of which 20-valent pneumococcal conjugate vaccine is the first listed.
NCT07135427 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT07135427 about?
NCT07135427 is a clinical study titled "Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency". The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will c...
What is the current status of trial NCT07135427?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-09-03. Estimated completion is 2027-06.
What conditions does trial NCT07135427 study?
This clinical trial studies the following conditions: COPD, Alpha 1-Antitrypsin, Antibody Deficiency.
What interventions are being tested in trial NCT07135427?
The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07135427?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07135427 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
COMPLETED · Phase 4
-
Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients
COMPLETED · Phase 4
-
Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 4
-
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COMPLETED · Phase 4
-
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.